BRAF(V600E)-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities
- Author(s)
- Piercey, O; Tie, J; Hollande, F; Wong, HL; Mariadason, J; Desai, J;
- Journal Title
- Clinical Colorectal Cancer
- Publication Type
- Apr 28 epub ahead of print
- Abstract
- BRAF(V600E)-mutant metastatic colorectal cancer represents a distinct molecular phenotype known for its aggressive biological behavior, resistance to standard therapies, and poor survival rates. Improved understanding of the biology of the BRAF oncogene has led to the development of targeted therapies that have paved the way for a paradigm shift in managing this disease. However, despite significant recent advancements, responses to targeted therapies are short-lived, and several challenges remain. In this review, we discuss how progress in treating BRAF(V600E)-mutant metastatic colorectal cancer has been made through a better understanding of its unique biological and clinical features. We provide an overview of the evidence to support current treatment approaches and discuss critical areas of need and future research strategies that hold the potential to refine clinical practice further. We also discuss some challenging aspects of managing this disease, particularly the complexity of acquired resistance mechanisms that develop under the selective pressure of targeted therapies and rational strategies being investigated to overcome them.
- Publisher
- Elsevier
- Keywords
- Bowel cancer; MAPK pathway; Predictive biomarkers; Resistance mechanisms; Targeted therapy
- Research Division(s)
- Personalised Oncology
- PubMed ID
- 38816264
- Publisher's Version
- https://doi.org/10.1016/j.clcc.2024.04.004
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-06-24 11:29:59
Last Modified: 2024-06-24 11:34:39